A retrospective real-world analysis of 71 eyes with macular edema secondary to retinal vein occlusion (ME-RVO) found the dexamethasone intravitreal implant (Ozurdex; Allergan) improved anatomic outcomes across treatment-naive, early-switch, and late-switch eyes, though functional gains were concentrated in naive and early-switch patients.¹ Eyes were followed for 12 months after DEX implant initiation. Multivariate analysis identified baseline best-corrected visual acuity (BCVA), not the timing of the switch from anti-VEGF therapy, as the main independent predictor of functional improvement.
The study, published in the European Journal of Ophthalmology, addresses an active question in RVO management: when anti-VEGF response is suboptimal, does switching to a corticosteroid implant sooner rather than later change the visual outcome?¹ By including a treatment-naive comparison arm alongside switch cohorts, the authors aimed to clarify whether switching window or baseline visual status drives recovery.
Study design and visual acuity results
Patients were classified into three groups based on prior anti-VEGF exposure: naive eyes with no prior intravitreal therapy, early-switch (ES) eyes transitioned to DEX implant after three or fewer anti-VEGF injections, and late-switch (LS) eyes transitioned after more than three injections.¹ Functional outcomes were measured by BCVA and anatomic outcomes by central macular thickness (CMT) on spectral-domain optical coherence tomography.
BCVA improved significantly at month two in naive and ES eyes (P < .05), according to the study authors, while LS eyes showed no significant BCVA change at this or later timepoints.¹ A two-line or greater BCVA gain occurred in 50% of naive eyes, a rate markedly higher than in either previously treated group. Naive patients maintained both functional and anatomic improvement throughout the 12-month follow-up period.
KEY FACTS
• Study topic: Real-world visual and anatomic outcomes of the dexamethasone intravitreal implant in retinal vein occlusion
• Journal and publication date: European Journal of Ophthalmology, June 19, 2026
• Study design: Retrospective, observational cohort study
• Population studied: Eyes with RVO-associated macular edema treated with the DEX implant (Ozurdex), stratified as naïve, early switch, or late switch
• Intervention: Dexamethasone intravitreal implant (0.7 mg)
• Primary outcome: Visual acuity and central retinal thickness changes across treatment groups
• Key result: All three groups demonstrated BCVA and anatomic improvements; earlier switching from anti-VEGF therapy was associated with greater visual gains than late switching
• Major limitation: Retrospective design with potential for selection bias and confounding by indication
Anatomic outcomes and predictors of visual response
All three groups, including LS eyes, demonstrated a significant early reduction in CMT at month two (P < .05), indicating DEX implant produced anatomic benefit independent of prior treatment history or switch timing.¹ This anatomic response in LS eyes occurred despite the absence of a corresponding functional gain, a dissociation the study authors highlight as clinically relevant for counseling patients who switch later in their treatment course.
Anatomical and visual improvement are related but not always equivalent, Sergio Copete, MD, PhD, FEBO, explains to Ophthalmology Times Europe, noting that retinal thickness can improve substantially in eyes with longstanding edema even when irreversible damage limits visual recovery. Copete is a co-author of the study and is affiliated with the Ophthalmology Department at University Hospital Complex of Albacete, Spain. "OCT findings and visual acuity should therefore be viewed as complementary outcomes rather than interchangeable ones." he says.
On multivariate analysis, baseline BCVA emerged as the main independent determinant of functional response, while switching timing did not reach significance as a predictor.¹ The authors state this finding suggests visual outcomes after DEX implant are driven primarily by a patient's baseline visual status rather than by how many anti-VEGF injections preceded the switch. “The key question is whether the patient is responding adequately,” Copete says. “If macular edema persists despite treatment, clinicians should reassess the strategy rather than continue an ineffective regimen indefinitely. Our findings support individualized decision-making rather than a fixed switching threshold,” Copete added. The source abstract did not report intraocular pressure elevation or cataract progression data; these safety outcomes were not available for this summary.
Clinical context
Anti-VEGF agents—including ranibizumab, aflibercept, and bevacizumab—are widely accepted as first-line therapy for RVO-associated macular edema and have demonstrated robust visual gains in pivotal trials.² However, a clinically relevant proportion of patients exhibit persistent or recurrent edema despite repeated injections, prompting interest in corticosteroid-based alternatives.
The DEX implant delivers sustained-release dexamethasone over approximately 4 to 6 months and has regulatory approval for RVO-associated macular edema. Its use as a primary or rescue therapy remains an area of active discussion given the balance between efficacy, IOP effects, and injection frequency. Copete urges caution in interpreting the study's findings on this question, noting it was not designed to compare DEX implant with anti-VEGF therapy as a first-line treatment. Still, he says the results point toward individualized treatment decisions rather than fixed treatment algorithms. Anti-VEGF therapy remains standard first-line care for most patients, Copete notes, but prolonging treatment despite an inadequate response is not always the right approach.
The findings position baseline visual acuity, rather than treatment sequence, as a clinically actionable marker for anticipating DEX implant response in anti-VEGF partial responders. "In selected cases, particularly when inflammatory mechanisms appear to play a prominent role or when the anatomical response is clearly suboptimal, earlier consideration of dexamethasone implant may be reasonable," Copete says. "Ultimately, the question may not be when to switch, but which patient is most likely to benefit from each treatment strategy," he adds. Prospective trials directly comparing early versus late switch strategies, stratified by baseline BCVA, would help determine whether this real-world signal holds in a controlled setting.
References
1. Real-world outcomes of naïve, early switch and late switch eyes treated with dexamethasone intravitreal implant for retinal vein occlusion. Eur J Ophthalmol. Published online June 19, 2026. https://journals.sagepub.com/doi/10.1177/11206721261461913
2. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041-2049. doi:10.1016/j.ophtha.2011.02.038
